Background on TelintraTelintra is an investigational agent in development for the treatment of a variety of neoplastic and non-neoplastic hematologic disorders, including myelodysplastic syndrome (MDS), and has demonstrated significant improvement in the induction of growth and differentiation of hematologic precursor stem cells as well as an increase in apoptosis of malignant cells. Telintra is an inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1), a negative regulator of JNK. Treatment of human cells with Telintra leads to the activation of JNK, which promotes the growth and differentiation of hematopoietic stem cell precursors. Telintra treatment has shown significant improvement in neutrophil levels in several clinical trials in MDS. More information about Telintra may be found at www.telik.com.
Telik Announces Publication Of A Report Of Complete Response Of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment With Telintra®
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.